To individualize the treatment of triple-negative breast cancer patients, we recommend to use a predictive biomarker focusing on a subpopulation of the TILs, such as CD8, which has shown to provide more consistent results in the TNBC subgroup in previous studies. Here, CD8A is linked to triple-negative breast carcinoma.